A Systematic Review of Clinical Trials in Uveitis: Lessons Learned

References

• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336. doi:10.1136/bjo.80.4.332.
   PubMed Web of Science ®Google Scholar
• Denniston AK, Holland GN, Kidess A, et al. Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. Orphanet J Rare Dis. 2015;10(1):97. doi:10.1186/s13023-015-0318-6.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;(340):c332.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–189. doi:10.1016/j.jclinepi.2021.03.001.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(3):478–486 e471. doi:10.1016/j.ajo.2013.05.002.
   PubMed Web of Science ®Google Scholar
• Qian Y, Qu Y, Gao F, et al. Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-A when combined with glucocorticoid in the treatment of refractory behcet’s uveitis: a randomized controlled prospective study. Front Pharmacol. 2021;12:699903. doi:10.3389/fphar.2021.699903.
   PubMed Web of Science ®Google Scholar
• Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020;127(7):948–955. doi:10.1016/j.ophtha.2020.01.006.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the periocular vs. intravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology. 2019;126(2):283–295. doi:10.1016/j.ophtha.2018.08.021.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis. Jama. 2019;322(10):10. doi:10.1001/jama.2019.12618.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787. doi:10.1016/j.ophtha.2012.09.040.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gul A. Use of gevokizumab in patients with behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023–1033. doi:10.1080/09273948.2017.1421233.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology. 2019;126(4):601–610. doi:10.1016/j.ophtha.2018.10.033.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Pavesio CE, Study I. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology. 2020;127(10):1395–1404. doi:10.1016/j.ophtha.2020.04.001.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal sirolimus for noninfectious uveitis: a phase III sirolimus study assessing double-masKed Uveitis TReAtment (SAKURA). Ophthalmology. 2016;123(11):2413–2423. doi:10.1016/j.ophtha.2016.07.029.
   PubMed Web of Science ®Google Scholar
• Nguyen Q, Merrill P, Clark WL. Efficacy and safety results from the SAKURA program: two phase III studies of intravitreal sirolimus every other month for non-infectious uveitis of the posterior segment. Association for Research in Vision and Ophthalmology Annual Meeting; 2017; Baltimore, MD.
   Google Scholar
• Madow B, Galor A, Feuer WJ, Altaweel MM, Davis JL. Validation of a photographic vitreous haze grading technique for clinical trials in uveitis. Am J Ophthalmol. 2011;152(2):170–176 e171. doi:10.1016/j.ajo.2011.01.058.
   PubMed Web of Science ®Google Scholar
• Hornbeak DM, Payal A, Pistilli M, et al. Interobserver agreement in clinical grading of vitreous haze using alternative grading scales. Ophthalmology. 2014;121(8):1643–1648. doi:10.1016/j.ophtha.2014.02.018.
   PubMed Web of Science ®Google Scholar